Table 2: Anti-GPC Ab levels and other autoantibodies.
RA (n = 45) | AITD (n = 36) | Control (n = 44) | 'p' value | |
Number of Anti-GPC Ab > 24.9 Units* (Prevalence %) | 7 (15.6%) | 4 (11.1%) | 8 (18.2%) | |
Anti-GPC Ab levels (Units) | 23.7 ± 18.8 | 18.3 ± 22.2 | 22.6 ± 25.5 | 0.538 |
Number of Anti-TPO Ab > 34 International Units/mL*(Prevalence %) | 4 (8.9%) | 12 (33.3%) | 7 (15.9%) | |
Anti-TPO Ab levels (International Units/mL) | 15.1 ± 11.1 | 287.5 ± 949.5 | 46.4 ± 146.1 | 0.087 |
Anti-nuclear antibody titer over 1:80 | 8 | 1 | 2 | |
Anti-CCP IgG levels (Units) | 145.1 ± 103.7 | 11.1 ± 5.6 | 11.5 ± 7.6 | < 0.001 |
Number of RF > 15 International Units/mL (Prevalence %) | 31 (68.9%) | 1 (2.8%) | 4 (9.0%) | |
RF value (International Units/mL) | 73.0 ± 71.0 | 10.0 ± 4.2 | 14.4 ± 20.9 | < 0.001 |
Key: *Threshold at which anti-GPC or anti-TPO antibodies as well as rheumatoid factor (RF) were counted as "positive" were determined by established ranges provided by our reference lab.